Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 15/20 | 0.87 |
| ▸ | CDK7 | P50613 | 13/20 | 0.79 |
| ▸ | CDK2 | P24941 | 18/20 | 0.72 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.72 |
| ▸ | CCNH | P51946 | 6/20 | 0.72 |
| ▸ | MNAT1 | P51948 | 6/20 | 0.72 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.72 |
| ▸ | CCNK | O75909 | 1/20 | 0.72 |
| ▸ | CDK14 | O94921 | 1/20 | 0.72 |
| ▸ | CDK1 | P06493 | 1/20 | 0.72 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.72 |
| ▸ | CCNC | P24863 | 1/20 | 0.72 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.72 |
| ▸ | CDK8 | P49336 | 1/20 | 0.72 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.72 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.72 |
| ▸ | CDK16 | Q00536 | 1/20 | 0.72 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.72 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.72 |
| ▸ | CCNY | Q8ND76 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20583125 | 1.00 | CDK9 (0.87) | CDK9CDK7CDK2CCNT1CCNH | |
| SCHEMBL20583216 | 0.93 | CDK9 (1.00) | CDK9CDK7CDK2CCNT1CCNH | |
| SCHEMBL20583219 | 0.93 | CDK9 (1.00) | CDK9CDK7CDK2CCNT1CCNH | |
| SCHEMBL20583131 | 0.92 | CDK9 (0.86) | CDK9CDK7CDK2CCNT1CCNH | |
| SCHEMBL20583133 | 0.92 | CDK9 (0.86) | CDK9CDK7CDK2CCNT1CCNH | |
| SCHEMBL20583090 | 0.89 | CDK9 (0.81) | CDK9CDK7CDK2CCNT1CCNH | |
| SCHEMBL20583094 | 0.89 | CDK9 (0.81) | CDK9CDK7CDK2CCNT1CCNH | |
| SCHEMBL22055545 | 0.88 | CDK7 (1.00) | CDK9CDK7CDK2CCNT1CCNH | |
| SCHEMBL22055743 | 0.88 | CDK7 (1.00) | CDK9CDK7CDK2CCNT1CCNH | |
| SCHEMBL20583234 | 0.86 | CDK9 (0.65) | CDK9CDK7CDK2CCNT1CCNH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230114207-A1 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| EP-4019515-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | Dana-Farber Cancer Institute, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-4019515-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | Dana-Farber Cancer Institute, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220055998-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220055998-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-11142507-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-11142507-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-20200172499-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-20200172499-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-20180362483-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11142507-B2 | Inhibitors of cyclin-dependent kinases | CDK1, CDK13, CDK3 | CDK9 22/4885CDK7 9/4885CDK2 5/4885 |
| US-20200172499-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK1, CDK13, CDK3 | CDK9 22/4885CDK7 9/4885CDK2 5/4885 |
| US-20180362483-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK1, CDK13, CDK3 | CDK9 22/4885CDK7 9/4885CDK2 5/4885 |
| US-20220055998-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK1, CDK13, CDK3 | CDK9 22/4885CDK7 9/4885CDK2 5/4885 |
| US-20230114207-A1 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | CDK7, CDC7, CDK8 | CDK9 5/4885CDK7 1/4885CDK2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.